Akkari and colleagues find that CD103+ regulatory T cells are highly abundant in the glioblastoma environment after checkpoint blockade restraining therapy response, and show therapeutic benefit for combined Treg targeting with radio-immunotherapy. This evidence concerns the gene ITGAE and glioblastoma.